Thymosin alpha-1 is approved in over 35 countries for hepatitis treatment and carries one of the most extensive clinical records of any research peptide — including compelling COVID-19 mortality data from 2020. Here's what the research actually shows about its Toll-like receptor mechanism and who benefits most.